PepGen (PEPG) - Kapitalizatsiyaning foydaga nisbati
PepGen Inc. (PEPG) grafigidagi narx ko'rsatkichi, atrof-muhitga ta'siri -5.00 koeffitsienti bilan uchinchi tomon laboratoriyalarida chiqindilarni utilizatsiya qilish bilan cheklangan aktivning dinamikasini namoyish etadi. Ushbu biotexnologiya firmasi Duchenne mushak distrofiyasi uchun dori vositalarini mushak to'qimalariga samarali yetkazib berishni ta'minlovchi EDO tizimini ishlab chiqmoqda. Hozirgi vaqtda PepGen Inc. (PEPG) og'ir mushak patologiyalarini davolash uchun oligonucleotid agentlarining chiqarilishidan keladigan daromadlarni kutayotgan bir paytda, investitsiya daromadlariga tayanmoqda.
PepGen Inc. kompaniyasining tahliliy kesimlari
- aksiya narxi va konsensus maqsadli narx:
- bozor kapitallashuvi ko'rsatkichlari:
- xususiy kapitalning balans qiymati ko'rsatkichlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati PepGen Inc.|PEPG - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati ko'rsatkichi PepGen Corp|PEPG - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati PepGen Inc.|PEPG - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz hajmi PepGen|Shoshilinch likvidlik koeffitsiyenti pepgen.com
- sof daromad va qiymat multiplikatorlari ko'rsatkichlari:
PEPG - Sof foyda|Kelajakdagi foyda PepGen Inc.|PEPG - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning prognoz qilingan foydaga nisbati PepGen Corp|PEPG - Narxning foydaga va o‘sish sur’atiga nisbati|Kompaniya qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati PepGen Inc.|PEPG - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda PepGen|PEPG - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik dinamikasi pepgen.com|PEPG - Joriy yilda foyda o'sishi|Keyingi yil uchun bitta aksiya uchun sof foyda o'sishi prognozi PepGen Inc.
Kompaniyaning umumiy tahlili:pepgen.com - PEPG
PepGen Inc. o'zining EDO platformasi orqali genetik nevrologiya nishasini nazorat qiladi, bu esa mushak distrofiyasi terapiyalariga bo'lgan noelastik talabni ta'minlaydi. Ushbu foyda va narx nisbati bir dollar sof daromadning bozor qiymatini raqamlashtiradi, bu esa investorlarga ushbu grafik dinamikasi orqali adolatli baholashni tahlil qilish yo'li bilan aktivlarning haddan tashqari qiziganini aniqlash va fatally yo'qotishlarning oldini olish imkonini beradi.
Muhim raqobatchilar
biogen.com - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori NBIX|RGC - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati Axsome Therapeutics Inc AXSM|ACAD (ACADIA Corp) - Kapitalizatsiyaning sof foydaga nisbati|Xenon Pharmaceuticals - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti vikingtherapeutics.com (VKTX)|SUPN: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Catalyst Pharma (CPRX)|Narxning foydaga nisbati Denali Therapeutics Inc|Narx-foyda multiplikatori HRMY (Harmony Corp)|Narx-foyda koeffitsiyenti BHVN (Biohaven Ltd.)|AMLX (amylyx.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori TRVI (Trevi Therapeutics, Inc.)|Biznesning o‘zini qoplash muddati Praxis Precision Medicines Inc (PRAX)|AVXL - Narxning foydaga nisbati|CBLL (CeriBell EEG) - Narx-foyda multiplikatori|PRTA: P/E multiplikatori|Narx-foyda koeffitsiyenti Alector|Narx-foyda koeffitsiyenti ANNX|Omeros Corp. (OMER) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Neurogene Corp (NGNE)|ACIU: Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori VYGR (Voyager Therapeutics)|neumoratx.com (NMRA) - Kapitalizatsiyaning foydaga nisbati|SCLX - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati TVGN|ACOG: P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Cognition Therapeutics Inc. CGTX|Narxning foydaga nisbati Inhibikase Therapeutics|Narx-foyda multiplikatori SAVA (cassavasciences.com)|P/E multiplikatori ASRT|COYA - Kapitalizatsiyaning foydaga nisbati|Vistagen - Narx-foyda koeffitsiyenti|P/E multiplikatori Ovid Therapeutics Inc OVID|ABOS - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati CRVO (cervomed.com)|alteritytherapeutics.com (ATHE) - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Clene (CLNN)|Narxning foydaga nisbati Jupiter Neurosciences|Relmada Corp - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori ANVS|GRCE - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati Firefly Neuroscience AIFF|KLTO (ANEW Medical) - Kapitalizatsiyaning sof foydaga nisbati|NeuroSense Therapeutics, Ltd. - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Reviva Pharmaceuticals, Inc. (RVPH)|MTVA: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati neuraxis.com (NRXS)|Narxning foydaga nisbati Helius Medical Technologies, Inc.|Narx-foyda multiplikatori PASG (Passage Bio Corp)|Narx-foyda koeffitsiyenti NEUP (Neuphoria Therapeutics Inc.)|NERV (Minerva) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ATHA (Athira Pharma, Inc.)|Biznesning o‘zini qoplash muddati addextherapeutics.com (ADXN)|ALZN - Narxning foydaga nisbati|CYCN (Cyclerion Therapeutics) - Narx-foyda multiplikatori|PTIX: P/E multiplikatori|Narx-foyda koeffitsiyenti Pasithea Therapeutics Corp.|Narx-foyda koeffitsiyenti CRGT|avenuetx.com (ATXI) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati BrainStorm Cell Therapeutics (BCLI)|CARA: Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori CHRO (Chromocell Therapeutics Corporation)|Eliem Therapeutics, Inc. (ELYM) - Kapitalizatsiyaning foydaga nisbati|ITCI - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati LBPH|MRNS: P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti NKGen Biotech Inc NKGN|Narxning foydaga nisbati NeuroBo|Narx-foyda multiplikatori SAGE (Sage Therapeutics Inc)|P/E multiplikatori SNPX|TRVN - Kapitalizatsiyaning foydaga nisbati|Vigil Neuroscience, Inc. - Narx-foyda koeffitsiyenti|P/E multiplikatori anewmeds.com WENA|CERE - Narxning foydaga nisbati
